US pharmaceutical innovation in an international context

Salomeh Keyhani, Steven Wang, Paul Hebert, Daniel Carpenter, Gerard Anderson

Research output: Contribution to journalArticle

Abstract

Objectives. We explored whether the United States, which does not regulate pharmaceutical prices, is responsible for the development of a disproportionate share of the new molecular entities (NMEs; a drug that does not contain an active moiety previously approved by the Food and Drug Administration produced worldwide. Methods. We collected data on NMEs approved between 1992 and 2004 and assigned each NME to an inventor country. We examined the relation between the proportion of total NMEs developed in each country and the proportion of total prescription drug spending and gross domestic product {GDP) of each country represented. Results. The United States accounted for 42% of prescription drug spending and 40% of the total GDP among innovator countries and was responsible for the development of 43.7% of the NMEs. The United Kingdom, Switzerland, and a few other countries innovated proportionally more than their contribution to GDP or prescription drug spending, whereas Japan, South Korea, and a few other countries innovated less. Conclusions. Higher prescription drug spending in the United States does not disproportionately privilege domestic innovation, and many countries with drug price regulation were significant contributors to pharmaceutical innovation.

Original languageEnglish (US)
Pages (from-to)1075-1080
Number of pages6
JournalAmerican journal of public health
Volume100
Issue number6
DOIs
StatePublished - Jun 1 2010

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'US pharmaceutical innovation in an international context'. Together they form a unique fingerprint.

  • Cite this